EP0999757A1 - Nutritional composition for subjects under stress - Google Patents

Nutritional composition for subjects under stress

Info

Publication number
EP0999757A1
EP0999757A1 EP98929576A EP98929576A EP0999757A1 EP 0999757 A1 EP0999757 A1 EP 0999757A1 EP 98929576 A EP98929576 A EP 98929576A EP 98929576 A EP98929576 A EP 98929576A EP 0999757 A1 EP0999757 A1 EP 0999757A1
Authority
EP
European Patent Office
Prior art keywords
composition
carnitine
stress
alkanoyl
ginseng
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98929576A
Other languages
German (de)
English (en)
French (fr)
Inventor
Claudio Cavazza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma-Tau
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma-Tau
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau, Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma-Tau
Publication of EP0999757A1 publication Critical patent/EP0999757A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a nutritional composition or medical food for subjects in a debilitated state as a result of stress.
  • This syndrome afflicts all social classes, but mainly affects people involved in the production cycle, who often, as a result, are subject to greater competitive stress stimuli both in the work environment and in the conduct of their social relations.
  • stress syndrome is not a debilitating "disease” to the extent that it makes people bed-ridden, but it is certainly a frequent cause of people taking days off work. Since it afflicts a substantial number of individuals, it causes a considerable burden of economic damage to the entire community during the working year. Stress syndrome, which in the past was improperly called "nervous breakdown', is characterised, in the absence of active disease, by concomitant states of malaise, such as a lack of strength, debilitation, states of mental and physical fatigue, lack of concentration and attention, and lack of sexual vigour and libido.
  • Benzodiazepines are used to alleviate symptoms such as anxiety or irritability, but present the drawback of causing addiction as well as further depressing libido and sexual vigour, thus triggering a mechanism in male subjects of reproductive age which itself proves to be a cause of additional malaise.
  • L-carnitine when used for the treatment of patients undergoing regular dialysis treatment, also induces recovery of normal sexual function in such patients (De Felice SL, Lyons P, Gaf ⁇ ar MC, Sheridan MJ, Dial-Transplant, 1996, vol/iss/pg. 25/6 368-373).
  • Ginseng has been used in Chinese medicine for more than 2000 years for the treatment of sexual impotence and for other diseases. Also well known is the activity of yohimbine in improving sexual function; see, for example, "Clinical Studies in Impotence”: K Reid et al., Lancet 2, 421-423 (1987). Guarana is used by Brazilian indigenous populations for the preparation of a stimulating beverage (Pharmacognosy, Edward P Claus, Varro E Tyler, Lynn R Brady, 6th edition pp. 292-293). Damiana has also long been known to be endowed, according to popular belief, with stimulant activity (J Psychoactive Drugs 16 (3): 267-268, 1984).
  • the purpose of the present invention is now to provide a therapeutic medical food suitable for alleviating and treating states of malaise caused by stress and for promoting sexual vigour.
  • the therapeutic medical food of the invention comprises the following compounds in combination:
  • ginseng natural extract of Panax ginseng
  • yohimbine natural extract of Corynanthe yohimbe
  • damiana natural extract of Turnera diffusa, ⁇ ar. aphrodisiaca
  • the alkanoyl L-carnitine should preferably be chosen from among the group comprising acetyl, propionyl, butyryl, valeryl and isovaleryl L-carnitine or one of its pharmacologically acceptable salts.
  • pharmacologically acceptable salt of L- camitine or of an alkanoyl L-carnitine is any salt of these with an acid which does not give rise to unwanted toxic or side effects.
  • acids are well known to pharmacologists and experts in pharmacy.
  • Non-limiting examples of pharmacologically acceptable salts of L-carnitine or of the alkanoyl L-carnitines are chloride, bromide, orotate, acid aspartate, acid citrate, acid phosphate, fumarate and acid fumarate, lactate, maleate and acid maleate, acid oxalate, acid sulphate, glucose phosphate, tartrate and acid tartrate.
  • the components of the combination according to the invention exhibit an unexpected potent synergistic effect which brings about an improvement in physical performance and in the mental and physical condition of patients suffering from stress syndrome.
  • Very important and surprising is the synergistic effect shown by the combination of ginseng, yohimbine and L-carnitine in restoring sexual vigour and libido,
  • the effect of the combination is, in fact, distinctly superior to the sum of the effects of the individual components.
  • L-carnitine and lecithin of soya favour the metabolisation of fatty acids, exerting a hypolipaemic effect on the body, which, though having no direct repercussions in terms of improving stress syndrome, is aimed at enhancing the individual's general state of health.
  • the weight-to-weight ratio of L-carnitine or of an alkanoyl L- carnitine to ginseng, yohimbine, guarana and damiana may vary over a broad range, This ratio should preferably range from 1:0.1:0.0025:0.1:0.1 to 1 : 10:0.25: 100:100.
  • One preferred ratio is
  • composition according to the invention may additionally contain vitamins, metals, coenzymes, inorganic or organic antioxidants or their precursors.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
EP98929576A 1997-07-16 1998-07-10 Nutritional composition for subjects under stress Withdrawn EP0999757A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM970435 1997-07-16
IT97RM000435A IT1293539B1 (it) 1997-07-16 1997-07-16 Composizione nutritiva per soggetti in stato di debilitazione causato da stress
PCT/IB1998/001056 WO1999003364A1 (en) 1997-07-16 1998-07-10 Nutritional composition for subjects under stress

Publications (1)

Publication Number Publication Date
EP0999757A1 true EP0999757A1 (en) 2000-05-17

Family

ID=11405180

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98929576A Withdrawn EP0999757A1 (en) 1997-07-16 1998-07-10 Nutritional composition for subjects under stress

Country Status (11)

Country Link
EP (1) EP0999757A1 (cg-RX-API-DMAC7.html)
JP (1) JP2001510026A (cg-RX-API-DMAC7.html)
KR (1) KR20010021694A (cg-RX-API-DMAC7.html)
CN (1) CN1263439A (cg-RX-API-DMAC7.html)
AU (1) AU727448B2 (cg-RX-API-DMAC7.html)
CA (1) CA2296540A1 (cg-RX-API-DMAC7.html)
HU (1) HUP0004526A3 (cg-RX-API-DMAC7.html)
IT (1) IT1293539B1 (cg-RX-API-DMAC7.html)
PL (1) PL338079A1 (cg-RX-API-DMAC7.html)
SK (1) SK181999A3 (cg-RX-API-DMAC7.html)
WO (1) WO1999003364A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT410277B (de) * 2001-02-22 2003-03-25 Peter Dr Frigo Getränk
LV12978B (en) * 2001-09-07 2003-05-20 Ivars Kalvins Pharmaceutical composition
ITRM20010708A1 (it) * 2001-12-04 2003-06-04 Sigma Tau Ind Farmaceuti Uso di una alcanoil l-carnitina per il trattamento della disfunzione erettile.
RU2355192C2 (ru) * 2002-09-28 2009-05-20 Фарматон С.А. Композиция, содержащая экстракты panax ginseng и paullinia cupana
DE102005053241A1 (de) * 2005-11-08 2007-05-16 Schwabe Willmar Gmbh & Co Extrakte aus der Rinde von Corynanthe-Arten und deren Verwendung sowie diese Extrakte enthaltende Arzneimittel, diätetische Lebensmittel und pharmazeutische Zubereitungen
WO2009066712A1 (ja) * 2007-11-21 2009-05-28 Kracie Pharma, Ltd. アロマターゼ阻害剤
JP6446265B2 (ja) * 2014-12-26 2018-12-26 花王株式会社 固形状組成物
CN113116898A (zh) * 2021-04-20 2021-07-16 北京天玺宝科技有限公司 一种具有减肥功能的包含左卡尼汀或乙酰左卡尼汀和育亨宾的组合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5626849A (en) * 1995-06-07 1997-05-06 Reliv International, Inc. Weight loss composition for burning and reducing synthesis of fats
FR2748659B1 (fr) * 1996-05-14 1998-07-24 Lvmh Rech Composition topique amincissante
US5744187A (en) * 1996-12-16 1998-04-28 Gaynor; Mitchel L. Nutritional powder composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9903364A1 *

Also Published As

Publication number Publication date
CA2296540A1 (en) 1999-01-28
IT1293539B1 (it) 1999-03-01
SK181999A3 (en) 2000-10-09
WO1999003364A1 (en) 1999-01-28
JP2001510026A (ja) 2001-07-31
CN1263439A (zh) 2000-08-16
AU727448B2 (en) 2000-12-14
HUP0004526A3 (en) 2001-11-28
PL338079A1 (en) 2000-09-25
ITRM970435A0 (cg-RX-API-DMAC7.html) 1997-07-16
HUP0004526A2 (hu) 2001-04-28
AU7927798A (en) 1999-02-10
KR20010021694A (ko) 2001-03-15
ITRM970435A1 (it) 1999-01-16

Similar Documents

Publication Publication Date Title
EP1057483B1 (en) Composition comprising theanine
KR100680121B1 (ko) (리소-)포스파티딜세린을 포함하는 온혈동물에서 스트레스상태의 예방 및 치료용 제제
JP4166951B2 (ja) 脳性および加齢性疾患の予防または治療のためのカルニチンおよびレスベラトロールの組み合わせ
US20090011048A1 (en) Dietary Supplement For Promoting Removal Of Heavy Metals From The Body
CN101248873A (zh) 具有视力保护功能的饮用食品
US7674482B2 (en) Method and compositions for potentiating pharmaceuticals with amino acid based medical foods
KR102539374B1 (ko) 뇌 활성 증진용 조성물
JP5275251B2 (ja) 肝臓疾患を予防及び処置するための組合せ薬草の抽出物を含む組成物
KR100481188B1 (ko) 글루타민산염관련질환치료용알카노일-l-카르니틴의용도
US20060099239A1 (en) Dietary supplement for promoting removal of heavy metals from the body
AU727448B2 (en) Nutritional composition for subjects under stress
KR100711276B1 (ko) 주의력 결핍 증후군 치료에 있어서 포스파티딜세린의 사용
US5482712A (en) Galenic composition
JP2007500755A (ja) 月経前症候群の症状を抑える方法
US20030194453A1 (en) Dietary supplement
WO2002078616A2 (en) Methods for increasing serotonin levels by administering (-)-hydroxycitric acid
AU2002305132A1 (en) Methods for increasing serotonin levels by administering (-)-hydroxycitric acid
US20040157929A1 (en) Method for increasing serotonin levels in a person by administration of a composition incorporating(-)hydroxycitric acid, and related compositions thereof
MXPA00000442A (en) Nutritional composition for subjects under stress
US20060269623A1 (en) Herbal composition and method of use for promoting erections and treating erectile dysfunction in men
CZ200088A3 (cs) Nutriční přípravek pro stresované subjekty
KR20090024215A (ko) 인간의 성적 활동성을 향상시키기 위한 수단과 방법들
KR20120055159A (ko) 감국 추출물을 포함하는 불면 증상의 예방 및 개선용 조성물과 그의 제조방법
KR20230106783A (ko) 초임계유체 추출법을 이용한 혼합추출물을 유효성분으로 함유하는 남성 성기능 개선용 조성물
WO2008152624A2 (en) Herbal energy-enhancing formulation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991227

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 19991227;LT PAYMENT 19991227;LV PAYMENT 19991227;MK PAYMENT 19991227;RO PAYMENT 19991227;SI PAYMENT 19991227

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 20011016

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1028525

Country of ref document: HK